LBT 0.00% 1.4¢ lbt innovations limited

Technicals - Good breakout on increasing volume - early days, page-140

  1. 394 Posts.
    lightbulb Created with Sketch. 41

    Any Guess which Module might be Next up...
    Sounds Lucrative.

    Antimicrobial susceptibility testing (AST) has gained widespread popularity worldwide in accelerating initiation of the targeted antimicrobial therapy used for patients affected from infections. Although new and rapid antimicrobial susceptibility testing technologies, such as genomic approaches, digital imaging, and phenotyping methods, have been studied in the recent past, there hasn’t been a single breakthrough in the development of rapid AST platform.

    This is mainly because of barriers that prevent timely development & implementation of rapid antimicrobial susceptibility testing platform. Industry experts across the globe have been focusing on utility of new approaches, uptake of novel tools, target product profile optimization, and validation of new technologies against the reference methods that extend beyond proof-of-concept phases.


    North America and Europe is expected to remain a lucrative region for growth of the antimicrobial susceptibility testing market. Growing awareness about treatment options available, and continuous research efforts toward development of new advanced drugs, are some of the key factors underpinning demand for antimicrobial susceptibility testing in these regions.

    Asia-Pacific is also expected to hold potential for growth of the antimicrobial susceptibility testing market, driven by increasing number of infection-related cases in the region.

 
watchlist Created with Sketch. Add LBT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.